Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation-Reference-Cited by-同舟云学术

Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation

Published:2018-09 Issue:3 Volume:4 Page:102-108
ISSN:2405-5255
Container-title:Osteoporosis and Sarcopenia
language:en
Short-container-title:Osteoporosis and Sarcopenia

Author:

Tanaka Mizue,Itoh Soichiro^ORCID,Takeuchi Yasuhiro

Publisher

Elsevier BV

Subject

General Medicine

Reference20 articles.

1. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors;Rugo;Ann Oncol,2008

2. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen;Oyan;Med Hypotheses,2011

3. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial;Goss;J Clin Oncol,2013

4. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer;Howell;Lancet,2005

5. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis;Hadji;Crit Rev Oncol Hematol,2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vitamin D, Th17 Lymphocytes, and Breast Cancer;Cancers;2022-07-27

2. Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models;International Journal of Molecular Sciences;2021-03-09

3. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis;Breast Cancer;2021-01-02

4. Eldecalcitol;Reactions Weekly;2018-11